The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Xiaomeng FengWei GuoYinping WangJia LiYangzhi ZhaoLimei QuXu YanJunna LiQiang GuoKen H YoungOu BaiPublished in: Advances in therapy (2021)
BV is a promising treatment in patients with ALCL, AITL and PTCL-TFH in frontline treatment settings.